These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28219799)

  • 21. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
    Parsons TL; Marzinke MA
    J Pharm Biomed Anal; 2016 Nov; 131():333-344. PubMed ID: 27632783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma.
    Cozzi V; Charbe N; Baldelli S; Castoldi S; Atzori C; Cattaneo D; Clementi E
    Ther Drug Monit; 2016 Jun; 38(3):407-13. PubMed ID: 26885814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
    Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
    J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
    Else L; Watson V; Tjia J; Hughes A; Siccardi M; Khoo S; Back D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(19):1455-65. PubMed ID: 20427248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
    Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
    Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
    De Nicolò A; Simiele M; Pensi D; Boglione L; Allegra S; Di Perri G; D'Avolio A
    J Pharm Biomed Anal; 2015 Oct; 114():127-32. PubMed ID: 26037161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous determination of intracellular concentrations of tenofovir, emtricitabine, and dolutegravir in human brain microvascular endothelial cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
    Patel SH; Ismaiel OA; Mylott WR; Yuan M; Hauser KF; McRae M
    Anal Chim Acta; 2019 May; 1056():79-87. PubMed ID: 30797464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
    Mehta R; Lagishetty CV; Angelis K; Aylott A; Kahl L; Blair L; Matthews J; Wynne B; Crauwels H; Underwood M; Adkison KK
    Br J Clin Pharmacol; 2023 Jul; 89(7):2190-2200. PubMed ID: 36740580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients.
    De Nicolò A; Avataneo V; Rabbia F; Bonifacio G; Cusato J; Tomasello C; Perlo E; Mulatero P; Veglio F; Di Perri G; D'Avolio A
    J Pharm Biomed Anal; 2016 Sep; 129():535-541. PubMed ID: 27497654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
    Yamada E; Takagi R; Moro H; Sudo K; Kato S
    PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of a systematic UPLC-MS/MS method for simultaneous determination of three phenol impurities in ritonavir.
    Venugopal N; Vijaya Bhaskar Reddy A; Madhavi G
    J Pharm Biomed Anal; 2014 Mar; 90():127-33. PubMed ID: 24366213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS.
    Das Mishra T; Kurani H; Singhal P; Shrivastav PS
    J Chromatogr Sci; 2012 Aug; 50(7):625-35. PubMed ID: 22562821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
    Zheng Y; Lui G; Boujaafar S; Aboura R; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Hirt D; Gana I
    J Pharm Biomed Anal; 2021 Mar; 196():113923. PubMed ID: 33571728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study.
    Mangla B; Alam O; Rub RA; Iqbal M; Singh A; Patel KS; Kohli K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122260. PubMed ID: 32679526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.
    D'Avolio A; Siccardi M; Sciandra M; Baietto L; Bonora S; Trentini L; Di Perri G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(2):234-40. PubMed ID: 17964231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An UPLC-MS/MS method for determination of solasonine in rat plasma and its application of a pharmacokinetic and bioavailability study.
    Chen Y; Zhang S; Chen D; Zhou M; Zheng J; Xiang Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Mar; 985():1-5. PubMed ID: 25645955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.
    D'Avolio A; Simiele M; Siccardi M; Baietto L; Sciandra M; Oddone V; Stefani FR; Agati S; Cusato J; Bonora S; Di Perri G
    J Pharm Biomed Anal; 2011 Mar; 54(4):779-88. PubMed ID: 21071165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.